JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2001; 38:1741-1747
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Whittaker, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Przyklenk, K.
Right arrow Articles by Whittaker, P.

EXPERIMENTAL STUDY

No loss in the in vivo efficacy of ischemic preconditioning in middle-aged and old rabbits

Karin Przyklenk, PhD, FACC*,a, Guohu Li, MDa and Peter Whittaker, PhDa

a Heart Institute, Good Samaritan Hospital and the Department of Medicine, Section of Cardiology, University of Southern California, Los Angeles, California, USA

Manuscript received March 9, 2001; revised manuscript received July 17, 2001, accepted August 13, 2001.

* Reprint requests and correspondence: Dr. Karin Przyklenk, Heart Institute/Research, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, California 90017-2395 USA
karinp{at}dnamail.com

OBJECTIVES

We tested the hypothesis that cardioprotection with ischemic preconditioning (PC) is lost in the aging, or senescent, heart.

BACKGROUND

Although infarct size reduction with PC has been documented in virtually all models, a purported exception to this paradigm is the aging heart, the population in which cardioprotection is most relevant. However, no previous studies have assessed the concept of an age-associated loss in the efficacy of PC in an in vivo model of acute myocardial infarction in which definitive hallmarks of cardiovascular aging were demonstrated and a reduction of infarct size, the "gold standard" of PC, served as the primary end point.

METHODS

Using the in vivo rabbit model, three cohorts of animals were studied: adult (4 to 6 months old), middle-aged (~2 years old) and old (~4 years old) rabbits. Within each cohort we assessed: 1) infarct size (measured by tetrazolium staining and expressed as percent myocardium at risk) in control and PC groups; and 2) morphologic and functional hallmarks of cardiovascular aging (progressive myocyte hypertrophy, increased myocardial fibrosis and attenuated responsiveness to beta-adrenergic stimulation).

RESULTS

In adult animals, infarct size was significantly smaller in the PC group than in the control group (29 ± 4% vs. 57 ± 2%; p < 0.01). Although middle-aged and old rabbits exhibited all three archetypal indexes of cardiovascular aging, a comparable (~50%) reduction in infarct size with PC was evident in both cohorts.

CONCLUSIONS

These data provide the first in vivo evidence that infarct size reduction with PC is not precluded by increased cardiovascular age, per se.

Abbreviations and Acronyms
  AN = area of necrosis
  ANCOVA = analysis of covariance
  ANOVA = analysis of variance
  AR = area at risk of infarction
  dP/dtmax = peak positive LV dP/dt
  LV = left ventricular
  LV dP/dt = first derivative of LV pressure
  MI = myocardial infarction
  NE = norepinephrine
  PC = preconditioning




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
K. Przyklenk, M. Maynard, C. E. Darling, and P. Whittaker
Aging Mouse Hearts Are Refractory to Infarct Size Reduction With Post-Conditioning
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1393 - 1398.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
P. Ferdinandy, R. Schulz, and G. F. Baxter
Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning
Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. Boengler, I. Konietzka, A. Buechert, Y. Heinen, D. Garcia-Dorado, G. Heusch, and R. Schulz
Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43
Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1764 - H1769.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Bolli
Preconditioning: a paradigm shift in the biology of myocardial ischemia
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H19 - H27.
[Abstract] [Full Text] [PDF]


Home page
J. Gerontol. A Biol. Sci. Med. Sci.Home page
G. Kristo, Y. Yoshimura, B. J. Keith, R. M. Mentzer Jr., and R. D. Lasley
Aged Rat Myocardium Exhibits Normal Adenosine Receptor-Mediated Bradycardia and Coronary Vasodilation But Increased Adenosine Agonist-Mediated Cardioprotection
J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2005; 60(11): 1399 - 1404.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
F. Di Lisa and P. Bernardi
Mitochondrial function and myocardial aging. A critical analysis of the role of permeability transition
Cardiovasc Res, May 1, 2005; 66(2): 222 - 232.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. Juhaszova, C. Rabuel, D. B. Zorov, E. G. Lakatta, and S. J. Sollott
Protection in the aged heart: preventing the heart-break of old age?
Cardiovasc Res, May 1, 2005; 66(2): 233 - 244.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
S. G. Memtsoudis, A. H. S. The, and P. M. Heerdt
Autonomic Mechanisms in the Age-Related Hypotensive Effect of Propofol
Anesth. Analg., January 1, 2005; 100(1): 111 - 115.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
K. Przyklenk, G. Li, B. Z. Simkhovich, and R. A. Kloner
Mechanisms of myocardial ischemic preconditioning are age related: PKC-{epsilon} does not play a requisite role in old rabbits
J Appl Physiol, December 1, 2003; 95(6): 2563 - 2569.
[Abstract] [Full Text]


Home page
J Am Coll CardiolHome page
K. Przyklenk and G. Heusch
Late preconditioning against myocardial stunning: Does aspirin close the "second window" of endogenous cardioprotection?
J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1195 - 1197.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. A Kloner, M. T Speakman, and K. Przyklenk
Ischemic preconditioning: a plea for rationally targeted clinical trials
Cardiovasc Res, August 15, 2002; 55(3): 526 - 533.
[Full Text] [PDF]


Home page
StrokeHome page
N. J. Alkayed, T. Goyagi, H.-D. Joh, J. Klaus, D. R. Harder, R. J. Traystman, and P. D. Hurn
Neuroprotection and P450 2C11 Upregulation After Experimental Transient Ischemic Attack
Stroke, June 1, 2002; 33(6): 1677 - 1684.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Abete, D. de Santis, M. Condorelli, C. Napoli, and F. Rengo
A four-year-old rabbit cannot be considered the right model for investigating cardiac senescence
J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1701 - 1701.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Przyklenk and P. Whittaker
Reply
J. Am. Coll. Cardiol., May 15, 2002; 39(10): 1701 - 1702.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2001 by the American College of Cardiology Foundation.